Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Novel Cardiac Biopsy Scoring Tool to Predict Clinical Outcomes in Cardiac Light Chain (AL) Amyloidosis

Ujjawal H Gandhi, PhDMBBS, Hanna Von Haefen, Robert Hoffman, MD PhD, Alexandra Ritts, MD, Sharon Phillips, MSPH, Oluchi Ukaegbu, MD, Samuel Rubinstein, MD, Shelton Lacy Harrell, MSN, Stacey A. Goodman, MD MS, Daniel Lenihan, MD, David Slosky, MD, Rebecca Hung, MD PhD, Robert Frank Cornell, MD

Blood (2017) 130 (Supplement 1): 1881.

https://doi.org/10.1182/blood.V130.Suppl_1.1881.1881

Published: 2017

Journal Articles

Similar Outcomes of Early Failure Steroid Dependent Acute GvHD and Upfront Steroid Refractory Acute GvHD: Implications on Clinical Trials

Karina A Mendoza, BS, Heidi Chen, PhD, Brian G Engelhardt, MD, Bipin N. Savani, MD, Stacey A Goodman, MD MS, Jeremy Warner, MD MS, Adetola A. Kassim, MD MS, Michael Byrne, MD, Wichai Chinratanalab, MD, John P. Greer, MD, Carole Hunt, Madan Jagasia, MD MBBS, MS

Blood (2017) 130 (Supplement 1): 1975.

https://doi.org/10.1182/blood.V130.Suppl_1.1975.1975

Published: 2017

Journal Articles

Rain (Renal AL Amyloid Involvement And NEOD001): A Multicenter, Randomized, Phase 2b Study of NEOD001 in Previously Treated Subjects With Systemic AL Amyloidosis and Persistent Renal Involvement

Cindy Varga, MD BSc, Angela Dispenzieri, MD, Morie A. Gertz, MD, Stacey A Goodman, MD MS, Kristen Hsu, Leslie Inker, MD, Heather Landau, MD, Nelson Leung, MD, Joseph R. Mikhael, MD, Taimur Sher, MD, Brendan M Weiss, MD, Sandy W. Wong, MD, Jeffrey A Zonder, MD, Raymond L. Comenzo, MD

Blood (2017) 130 (Supplement 1): 5437.

https://doi.org/10.1182/blood.V130.Suppl_1.5437.5437

Published: 2017

Journal Articles

Prospective Study of Cardiac Events during Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma

Blood (2017) 130 (Supplement 1): 1855.

https://doi.org/10.1182/blood.V130.Suppl_1.1855.1855

Published: 2017

Journal Articles

Outcomes of a Novel Rituximab-Based Non-Ablative Conditioning Regimen for Hematopoietic Cell Transplantation in Severe Aplastic Anemia

Katie S Gatwood, PharmD, Kathryn A Culos, PharmD, Laura A Binari, MD, Brian G Engelhardt, MD, Adetola A. Kassim, MD MS, Michael Byrne, MD, Stacey A Goodman, MD MS, Wichai Chinratanalab, MD, Salyka M. Sengsayadeth, MD, John P. Greer, MD, Madan Jagasia, MD MBBS, MS, Bipin N. Savani, MD

Blood (2017) 130 (Supplement 1): 3210.

https://doi.org/10.1182/blood.V130.Suppl_1.3210.3210

Published: 2017

Journal Articles

Yearly Long-Acting Zoledronic Acid (Reclast) Is Safe and Effective for Treatment of Bone Loss after Hematopoietic Stem Cell Transplantation

Zhuoyan Li, MD, Samuel M Rubinstein, MD, Carey Clifton, ACNP, Leigh Ann Vaughan, ACNP, Melissa Logue, ACNP, Michael T. Byrne, DO, Adetola A. Kassim, MD MS, Brian G Engelhardt, MD, Wichai Chinratanalab, MD, Salyka Sengsayadeth, MD, Stephen J. Brandt, MD, Stacey A. Goodman, MD MS, John P. Greer, MD, Madan Jagasia, MD, Bipin N. Savani, MD

Blood (2016) 128 (22): 3438.

https://doi.org/10.1182/blood.V128.22.3438.3438

Published: 2016

Journal Articles

Increased Kidney Biopsy Scarring and Amyloid Deposition Predict Progression to Eskd in Patients with AL Amyloidosis

Rubinstein Samuel, MD, Agnes B Fogo, MD, Liping Du, PhD, Beatrice Concepcion, MD, Stacey A. Goodman, MD MS, Anthony Langone, MD, Daniel J. Lenihan, MD, Robert Frank Cornell, MD

Blood (2016) 128 (22): 5635.

https://doi.org/10.1182/blood.V128.22.5635.5635

Published: 2016

Journal Articles

Reduced Intensity Conditioning with Fludarabine, Cyclophosphamide, and Rituximab Is Associated with Improved Outcomes When Compared to Fludarabine and Busulfan Following Allogeneic Hematopoietic Cell Transplantation for Lymphoid Malignancies

Vanessa E Kennedy, BS, Bipin N. Savani, MD, John P. Greer, MD, Adetola A. Kassim, MD MS, Brian G Engelhardt, MD, Stacey A. Goodman, MD MS, Salyka M. Sengsayadeth, MD, Wichai Chinratanalab, MD, Madan H. Jagasia

Blood (2015) 126 (23): 4409.

https://doi.org/10.1182/blood.V126.23.4409.4409

Published: 2015

Journal Articles

Optimizing Anti-Thymocyte Globulin Dosing Based on Recipient Absolute Lymphocyte Count after Unrelated Allogeneic Hematopoietic Cell Transplant

Vanessa E Kennedy, BS, Heidi Chen, Bipin N. Savani, MD, John P. Greer, MD, Adetola A. Kassim, MD MS, Brian G Engelhardt, MD, Stacey A. Goodman, MD MS, Salyka M. Sengsayadeth, MD, Wichai Chinratanalab, MD, Madan H. Jagasia

Blood (2015) 126 (23): 4410.

https://doi.org/10.1182/blood.V126.23.4410.4410

Published: 2015

Journal Articles

Six-Minute Walk Test As a Measure of Functional Change after Chemotherapy in Cardiac AL Amyloidosis

Ilka Decker, MD MS, Oluchi C. Ukaegbu, MD, Stacey A. Goodman, MD MS, Daniel J. Lenihan, MD, Rebecca R Hung, MD, Adetola A. Kassim, MD MS, Shelton L. Harrell, MSN, ACNP-BC, Kevin McDonagh, MD, Sharon E. Phillips, MSPH, Kyle T Rawling, Samuel M Rubinstein, MD, Tarsheen K. Sethi, MD MS, Robert F Cornell, MD MS

Blood (2015) 126 (23): 1841.

https://doi.org/10.1182/blood.V126.23.1841.1841

Published: 2015

Journal Articles

Risk Factors for Cardiac Toxicities Associated with Proteasome Inhibitor Chemotherapy during Treatment of Multiple Myeloma

John H. Chen, Daniel J. Lenihan, MD, Sharon E. Phillips, MSPH, Madan H. Jagasia, Stacey A. Goodman, MD MS, Adetola A. Kassim, MD MS, Shelton L. Lacy, Kevin T. McDonagh, Javid J. Moslehi, MD, Tarsheen K. Sethi, MD MS, David A. Slosky, Oluchi C. Ukaegbu, MD, Robert F. Cornell

Blood (2015) 126 (23): 5363.

https://doi.org/10.1182/blood.V126.23.5363.5363

Published: 2015

Journal Articles

In the Era of Bortezomib-Based Chemotherapy the Presence of Minimal Residual Disease Predicts Progression Free Survival after Autologous Hematopoietic Cell Transplant

Robert F Cornell, MD MS, Jade E Jones, Claudio A. Mosse, Heidi Chen, Laura Dugger, Salil Goorha, Wichai Chinratanalab, Brian Engelhardt, Stacey A. Goodman, MD MS, John P Greer, Shelton Lacy, Adetola A. Kassim, MD MS, Kevin McDonagh, Bipin N. Savani, MD, Salyka Sengsayadeth, Madan Jagasia

Blood (2015) 126 (23): 5493.

https://doi.org/10.1182/blood.V126.23.5493.5493

Published: 2015

NARROW

Novel Cardiac Biopsy Scoring Tool to Predict Clinical Outcomes in Cardiac Light Chain (AL) Amyloidosis

Similar Outcomes of Early Failure Steroid Dependent Acute GvHD and Upfront Steroid Refractory Acute GvHD: Implications on Clinical Trials

Rain (Renal AL Amyloid Involvement And NEOD001): A Multicenter, Randomized, Phase 2b Study of NEOD001 in Previously Treated Subjects With Systemic AL Amyloidosis and Persistent Renal Involvement

Prospective Study of Cardiac Events during Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma

Outcomes of a Novel Rituximab-Based Non-Ablative Conditioning Regimen for Hematopoietic Cell Transplantation in Severe Aplastic Anemia

Yearly Long-Acting Zoledronic Acid (Reclast) Is Safe and Effective for Treatment of Bone Loss after Hematopoietic Stem Cell Transplantation

Increased Kidney Biopsy Scarring and Amyloid Deposition Predict Progression to Eskd in Patients with AL Amyloidosis

Reduced Intensity Conditioning with Fludarabine, Cyclophosphamide, and Rituximab Is Associated with Improved Outcomes When Compared to Fludarabine and Busulfan Following Allogeneic Hematopoietic Cell Transplantation for Lymphoid Malignancies

Optimizing Anti-Thymocyte Globulin Dosing Based on Recipient Absolute Lymphocyte Count after Unrelated Allogeneic Hematopoietic Cell Transplant

Six-Minute Walk Test As a Measure of Functional Change after Chemotherapy in Cardiac AL Amyloidosis

Risk Factors for Cardiac Toxicities Associated with Proteasome Inhibitor Chemotherapy during Treatment of Multiple Myeloma

In the Era of Bortezomib-Based Chemotherapy the Presence of Minimal Residual Disease Predicts Progression Free Survival after Autologous Hematopoietic Cell Transplant

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only